Avian Flu Treatment Market Insights Highlight Segment Expansion And Market Leadership

The avian flu treatment market is attracting growing attention as global health systems prioritize preparedness against zoonotic diseases. With advancements in vaccine technology and antiviral therapies, this sector is set for robust expansion. Let's explore the market's projected size, key players, emerging trends, and segmentation to understand its future trajectory.

Expected Market Size and Growth Outlook for the Avian Flu Treatment Market
The avian flu treatment sector is anticipated to experience significant growth over the coming years, reaching a market size of $20.6 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 8.2%. Factors fueling this growth include increasing investments in research on zoonotic diseases, the advancement of next-generation vaccines, global expansion of disease surveillance systems, heightened focus on rapid therapeutic responses, and greater collaboration between countries on pandemic readiness. Key trends shaping the market during the forecast period involve wider adoption of cutting-edge antiviral treatments, accelerated vaccine development platforms, increased use of monoclonal antibody therapies, expansion of early diagnosis and monitoring programs, and an intensified emphasis on preparing for pandemics.

The avian flu treatment market size has grown strongly in recent years. It will grow from $13.77 billion in 2025 to $15.04 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing incidence of avian influenza outbreaks, reliance on antiviral stockpiling strategies, government-led disease control initiatives, expansion of hospital-based infectious disease treatment, increased public health awareness.

Download a free sample of the avian flu treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16352&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Dominating the Avian Flu Treatment Market
Several major pharmaceutical and biotechnology companies are at the forefront of the avian flu treatment industry. These include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., and Takeda Pharmaceutical Company Limited.

Significant Corporate Moves Enhancing Avian Flu Treatment Options
In November 2025, Merck & Co. (MSD), a U.S.-based biopharmaceutical firm, announced its acquisition of Cidara Therapeutics, Inc. for $9.2 billion in cash. This strategic move aims to broaden Merck's respiratory and antiviral portfolio by incorporating Cidara's proprietary long-acting antiviral agent, CD388, which is designed for broad, durable influenza prevention. Cidara Therapeutics, also U.S.-based, develops drug-Fc conjugate (DFC) therapies using its Cloudbreak platform. CD388, their lead candidate, is a strain-agnostic antiviral currently undergoing Phase III clinical trials.

View the full avian flu treatment market report:
https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Collaborations Driving Innovation in the Avian Flu Treatment Market
Collaborative partnerships between pharmaceutical firms, research entities, and government organizations are becoming increasingly important to accelerate the development and improve the effectiveness of avian flu treatments. For example, in April 2024, CureVac N.V., a biotechnology company from Germany, teamed up with GSK plc, a UK pharmaceutical company, to develop a candidate vaccine targeting the influenza A (H5N1) virus. This pre-pandemic vaccine candidate seeks to address the threat of a future H5N1 outbreak. The joint Phase 1/2 clinical trial will evaluate safety, reactogenicity, and immune response in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85. CureVac's proprietary second-generation mRNA backbone encodes the influenza A H5 antigen for this monovalent vaccine.

Defining the Avian Flu Treatment Market Segmentation
This report divides the avian flu treatment market into several key segments:
By Type, the market includes Vaccines, Antiviral Agents, and Immunoglobulins.
Distribution Channels are categorized as Online Pharmacies and Offline Pharmacies.
End Users encompass Hospitals, Institutional Health Centers, and Clinics.

Further subcategories include:
Vaccines segmented into Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, DNA Vaccines, as well as Bivalent and Multivalent Vaccines.
Antiviral Agents broken down into Neuraminidase Inhibitors (e.g., Oseltamivir, Zanamivir), Polymerase Inhibitors, and Antiviral Combination Therapies.
Immunoglobulins include Human Immunoglobulin (IVIg), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, and Avian Flu-Specific Immunoglobulins.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.